News | December 12, 2007

WorldHeart Enters Strategic Alliance With Abiomed

December 13, 2007 - World Heart Corp., a developer of implantable mechanical circulatory support systems for chronic heart failure patients, announced its strategic alliance with Abiomed Inc., a leading manufacturer of devices for acute circulatory support.

WorldHeart and Abiomed currently serve complementary segments of the circulatory support market. This alliance is expected to benefit heart failure patients and treatment providers, promoting synergies between the two organizations in a number of areas, including:

- Products - WorldHeart's Novacor pulsatile LVAS and the Levacor Rotary VAD are designed to provide long-term support for chronic heart failure patients. Intended for use as a bridge to transplant or for destination (life-long) therapy, implant durations typically range from months to years. Abiomed markets a number of devices targeting primarily recovery applications,where support duration is measured in hours, days or months.The portfolios of the two companies collectively span the full spectrum of mechanical circulatory support needs, with implant durations ranging from hours to years, and from partial to total support.
- Clinical Relationships - The recipients of WorldHeart's chronic support devices are under the care of heart failure cardiologists and cardiac surgeons. Abiomed's products are administered by interventional cardiologists as well as cardiac surgeons.Collectively, the two companies have access to a broad base of clinical customers addressing a wide range of cardiac conditions.
- Marketing and Clinical Support - The two companies expect to be able to reach a broader customer base and provide an efficient and high level of clinical support.
- Technology - The companies also expect to explore opportunities for technology collaborations. The transcutaneous (across-the-skin) energy transfer system and implanted electronics developed for the AbioCor total heart potentially could be adapted to the Levacor, eliminating any wires through the skin to reduce the associated infection risk.

For more information: www. worldheart.com, www.abiomed.com

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init